# Rezo Therapeutics

> Rezo Therapeutics is a San Francisco biopharma company building small-molecule medicines from maps of disease-altered protein networks. Its Sequence to Systems to Drugs platform joins proteomics, genetics, structural biology, chemistry, bioinformatics and AI, with an initial focus on solid tumors and protein-protein interactions that conventional target-by-target discovery can miss.

- **Founded:** 2021
- **Headquarters:** San Francisco, United States
- **Founders:** Nevan Krogan (Co-founder and President; founding CEO), Kevan Shokat (Scientific co-founder), Sourav Bandyopadhyay (Co-founder and founding Chief Scientific Officer), Natalia Jura (Scientific co-founder), George Scangos (Co-founder and Board Chair), Norbert Bischofberger (Co-founder and board member)
- **Products:** Sequence to Systems to Drugs (SSD) platform, PPI foundation model and structural inference workflow, Precision oncology pipeline
- **Notable:** Launched publicly in November 2022 with a $78 million Series A led by SR One, a16z Bio + Health and Norwest Venture Partners., Built on roughly two decades of network-biology research from UCSF's Quantitative Biosciences Institute., Reported dynamic scale from zero to 500 Google Cloud TPUs across four regions through Union.ai orchestration.

## Products & services

- **Sequence to Systems to Drugs (SSD) platform** — An integrated discovery platform combining proteomics, genetics, structural biology, chemistry, bioinformatics, AI and machine learning to map disease networks, identify druggable protein interfaces and support small-molecule programs.
- **PPI foundation model and structural inference workflow** — A high-throughput system trained around protein-protein interaction data, paired with scalable structure prediction to prioritize disease-relevant complexes and ligandable interfaces.
- **Precision oncology pipeline** — Undisclosed preclinical therapeutic programs focused initially on solid tumors, mutation-specific biology, resistance mechanisms and protein-protein interactions.

## Achievements

- Launched publicly in November 2022 with a $78 million Series A led by SR One, a16z Bio + Health and Norwest Venture Partners.
- Built on roughly two decades of network-biology research from UCSF's Quantitative Biosciences Institute.
- Reported dynamic scale from zero to 500 Google Cloud TPUs across four regions through Union.ai orchestration.
- Reported storage cost reductions above 90% and compute reductions up to 67%; one MSA workflow fell from about $10,000 per month to hundreds of dollars.
- With NVIDIA's Fold-CP approach, reported predicting complexes up to 6,500 residues, covering 93% of the CORUM benchmark versus less than 30% with serial Boltz-1x.
- Co-hosted UCSF scientific meetings on mass spectrometry in 2024 and AI in biology in 2025.

## Latest updates

- **2026-03** — Rezo described its work with NVIDIA to use context parallelism and cuEquivariance for structural prediction of higher-order protein complexes.
- **2026-01** — A Union.ai case study detailed Rezo's cloud orchestration, including dynamic use of 500 TPUs across four regions and major storage and compute savings.
- **2025-08** — Derek Hicks was appointed CEO; co-founder Nevan Krogan became President.
- **2025-06** — Rezo and UCSF QBI co-hosted a two-day symposium on AI in biology at Mission Bay.
- **2024-05** — Rezo and UCSF QBI co-hosted a mass spectrometry symposium focused on emerging proteomic technologies.

## Links

- Website: https://rezotx.com/
- LinkedIn: https://www.linkedin.com/company/rezotx

---

Profile page: https://yespress.io/rezo-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-09-24